title: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease.
abstract: BACKGROUND
  Metabolic risk conferred by adiposity may be due to associated risk factor clustering.
  
  
  OBJECTIVE
  The objective of this study was to assess risk for diabetes or cardiovascular disease (CVD) stratified by body mass index (BMI) and the presence or absence of metabolic syndrome (MetS) or insulin resistance (IR).
  
  
  METHODS
  This was a community-based, longitudinal study of 2902 people (55% women, mean age 53 yr) without diabetes or CVD in 1989-1992 followed for up to 11 yr. We categorized subjects by normal weight (BMI < 25 kg/m(2)), overweight (25-29.9 kg/m(2)), or obese (>30 kg/m(2)) and by the National Cholesterol Education Program's Adult Treatment Panel MetS or the top quartile of homeostasis model IR. We used proportional hazard models to estimate risk relative to normal weight and no MetS or IR.
  
  
  METHODS
  Incident type 2 diabetes (treatment or fasting glucose > or = 7 mmol/liter, 141 events) or CVD (myocardial infarction, stroke, or claudication, 252 events) were measured.
  
  
  RESULTS
  Among 1056 normal-weight subjects, 7% had MetS and a risk factor-adjusted relative risk for diabetes of 3.97 (95% confidence interval, 1.35-11.6) and for CVD of 3.01 (1.68-5.41). Among 638 obese subjects, 37% did not have MetS or significantly increased risk. Obese subjects with MetS had an adjusted relative risk for diabetes of 10.3 (5.44-19.5) and for CVD of 2.13 (1.43-3.18). Results were similar in analyses of BMI-IR categories.
  
  
  CONCLUSIONS
  People with normal weight and MetS or IR or with obesity but no MetS or IR were not uncommon in our sample. Risk factor clustering or IR appear to confer much of the risk for diabetes or CVD commonly associated with elevated BMI.
authors.affiliation: General Medicine Division, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114, USA. jmeigs@partners.org
authors.forename: James B
authors.initials: JB
authors.lastname: Meigs
authors.forename: Peter W F
authors.initials: PW
authors.lastname: Wilson
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Fox
authors.forename: Ramachandran S
authors.initials: RS
authors.lastname: Vasan
authors.forename: David M
authors.initials: DM
authors.lastname: Nathan
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Sullivan
authors.forename: Ralph B
authors.initials: RB
authors.lastname: D'Agostino
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology*; D005215:Fasting; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007333:Insulin Resistance; D008137:Longitudinal Studies; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000453:epidemiology; D016016:Proportional Hazards Models; D012307:Risk Factors
chemical_list: D001786:Blood Glucose